Introduction
Atrial fibrillation (AF) is primarily a disease of the elderly. It has an overall population prevalence of $1%, but the prevalence increases markedly with age. 1 On the other hand, risk estimates of early-onset AF (diagnosed prior to 60 years of age) are only 3% for males and 1% for females. 2 In up to 30% of AF cases no predisposing condition can be identified and the disease has traditionally been classified as lone AF. 3 Familial clustering of AF, particularly of early-onset cases, is well recognized. We reported strong heritability among unselected AF cases and showed that first-degree relatives of Icelanders with earlyonset AF are nearly five times more likely to develop AF than the general population. 4 Mutations in several genes, identified through linkage and candidate gene studies, have been found in both familial and sporadic AF. 5 Most of these are ion channel genes. 5 In 2007, the first common sequence variants that associate with common AF, close to PITX2, were discovered through genome-wide association 6 and several have been found since, 5 including a variant in MYH6, encoding the alpha heavy chain subunit of cardiac myosin. 7 In this study, we used a large population-based resource of whole-genome sequence data to search for sequence variants that affect the risk of early-onset AF.
Methods
We have briefly described these data previously in a paper on wholegenome sequencing in Icelanders. 8 Here we present the findings in full, including detailed phenotypic data. The investigation was approved by the Icelandic Data Protection Authority and the National Bioethics Committee of Iceland. The study complies with the Declaration of Helsinki.
Study populations
The deCODE Icelandic AF population consisted of Icelanders diagnosed with AF (ICD 10 code I48 and ICD 9 code 427.3) according to electronic medical records (EMR) at Landspitali, The National University Hospital in Reykjavik and Akureyri Hospital (the two largest hospitals in Iceland) from 1987 to 2012. This analysis was restricted to 1799 cases diagnosed before age 60 years, comprised of 1183 single nucleotide polymorphism (SNP) chip-typed individuals and 616 close relatives (familial imputation, see Generation of genotype data below, see also Supplementary material online, Figure S1 ). 
Generation of genotype data
We have previously described methods to interrogate whole genomes of large numbers of Icelanders and to search for associations with various traits 8 (see also Supplementary material online). In brief, 137 445
Icelandic samples were genotyped with Illumina microarrays (chip-typed), a method to determine the alleles of predefined SNPs for each individual. Most of the chips used contained 600 000 SNPs. The whole genomes of 8453 chip-typed Icelanders were also sequenced using standard TrueSeq methodology (Illumina) to a mean depth of at least 10X (median 32X). This method determines the near-complete DNA sequence for each individual. The sequencing depth (coverage) refers to the average number of reads representing a given nucleotide in the reconstructed sequence. Genotypes of the 25.5 million sequence variants identified through sequencing (SNPs and indels) were then imputed into all chiptyped Icelanders and their close relatives (familial imputation) (Supplementary material online). Imputation refers to the statistical inference of unobserved genotypes using known haplotypes in the population.
Microsatellite genotyping
PCR amplifications were set up and pooled using Zymark SciClone ALH 500 robots. The sequences of the forward and reverse primers used for genotyping were TCACTGGGGATTGGAAGGTA and GGCATTGGT AGGGTTCTGG, respectively. Conditions for PCR reactions are described in the Supplementary material online. The PCR products were supplemented with an internal size standard and the fragments were separated and detected on an Applied Biosystems model 3730 sequencer, using Genescan (v. 3 .0) peak-calling software. Alleles were called using an internal allele-calling program. 9 
Association testing
Logistic regression was used to test for association between SNP genotypes and disease. Disease status was treated as the response and the expected allele counts from imputation as covariates for the multiplicative model. For the recessive model, the product of the maternal and paternal expected minor allele counts was used as a covariate (Supplementary material online).
Inflation factor adjustment
In order to account for relatedness and stratification within the Icelandic case and control samples, we applied the method of genomic control based on chip markers. 10 The correction factor based on linkage disequilibrium (LD) score regression was 1.12 for the multiplicative model and 1.05 for the recessive model. All P values were adjusted accordingly.
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Age of the mutation
We estimated the age of the c.234delC mutation by examining the decay of LD between the mutation and neighbouring chip markers. 12 These age estimates were then corrected based on the Luria-Delbrück model. 13 A single estimate for the age of the mutation in generations was then obtained by taking the geometric mean of the age estimates for each SNP. This was multiplied by 30 to obtain an estimate of the age of the mutation in years.
Results
A single nucleotide deletion in MYL4 is associated with early-onset AF
We found that the two most significant associations with early-onset AF under the multiplicative model were with variants at previously reported loci, PITX2 6 and ZFHX3. 
significantly with early-onset AF ( Figure 1 and Supplementary material online, Table S1 ). This set of sequence variants associated with a large increase in the risk of early-onset AF [odds ratio (OR) estimated between 16 and 132]. Of these variants, only one is protein coding: a single basepair deletion (c.234delC) in MYL4 (NM_001002841 and NM_002476) with an allelic frequency of 0.58% (OR ¼ 121, 95% CI:
). This deletion results in a frameshift at amino acid 78 out of 197 (p.C78fs) truncating the encoded protein ( Figure 2 ). There was no other loss of function mutation (splice acceptor/donor, stop gain/loss, frameshift insert/deletion) seen in MYL4 in the 8453 sequenced Icelanders. Sequence variants in MYL4 have not been associated with arrhythmias or other diseases previously.
Within the 3.9Mb interval spanned by the sequence variants reaching genome-wide significance, the average coverage was >5X for 99.9% and >10X for 99.4% of exonic positions, sufficient coverage for a sequence variant with 0.58% minor allele frequency (expected 98 sequenced carriers) to be observed with high probability.
The test for association of c.234delC with early-onset AF was based on imputing the c.234delC genotype status into chip-typed individuals using a whole-genome sequenced sample of 8453 Icelanders as the basis for the imputation, 99 of whom were heterozygous for the deletion. The quality of imputation was high (information ¼ 0.95), estimated by a measure of imputation information (see Supplementary material online). To confirm the existence of the c.234delC deletion and to validate its imputation, we Figure 3 ), one of whom had been diagnosed with AF at age 56.
For verification of the AF diagnoses and more detailed phenotyping, a medical record review was performed for all eight Conserved amino acid residues are depicted as a dot (.) , the portion of the mutated protein rendered out of frame is within a box and missing residues as a cause of a premature stop codon are depicted as a dash (-). Secondary and tertiary protein structure properties are shown above and below the alignment, respectively (UniProtKB: P12829). homozygous carriers. This showed that the two homozygotes without AF diagnoses in EMR had in fact been diagnosed with AF prior to the initiation of electronic recording in 1987: a male at 15 years and the female at 53 years of age. In order to attach a significance level to this finding, we estimated the probability of these two individuals both being diagnosed with AF at the observed time in our Icelandic population (see Supplementary material online). We estimated the probability of a male being diagnosed with AF at the age of 15 as 1 in 10 000 and a female with a sister with early-onset AF being diagnosed at 53 as five in one hundred. Combination of these probabilities after conversion to z-scores gave a two-sided P value of 1.5 Â 10 À4 . Combined with the initial association, the recessive association of the MYL4 deletion with early-onset AF is highly significant (P ¼ 1.7 Â 10 À14 ) [Adding these two cases to the set of early-onset AF cases and performing the test for association creates an inflated level of significance (Supplementary material online, Table S1 ,
We also found, through detailed medical record review, that five of the six homozygotes with EMR diagnoses of AF had documented earlier onset than the EMR indicated ( Table 1) . All eight homozygous carriers of the MYL4 c.234delC frameshift deletion had thus been diagnosed with early-onset AF ( Table 1) . 
Three of the chip-typed homozygotes are full siblings (Figure 3) , diagnosed with AF at the ages of 14, 21 and 28 ( Table 1) . Another case presented with AF during pregnancy at age 21, but reported having had palpitations since 12 years of age.
To test for association of heterozygous carriers of c.234delC with AF, we removed the eight known homozygotes and repeated the multiplicative test. Significance was neither observed with early-onset AF (OR ¼ 1.09, 95% CI: 0.67-1.78, P ¼ 0.73) nor AF at any age (OR ¼ 1.22, 95% CI: 0.98-1.53, P ¼ 0.080).
The c.234delC variant was estimated to have been introduced to Iceland about 27 generations or approximately 807 years ago. 7, 12, 15 The variant is not present in the available 1000 Genomes data 16 or the Exome Variant Server data 17 and no carriers were found on genotyping c.234delC in AF sample sets from Hong Kong (258 AF cases, 2125 controls) and Norway (357 AF cases, 323 controls).
Clinical presentation of the MYL4 c.234delC deletion
Seven of the eight homozygotes had paroxysmal AF attacks following the initial diagnosis and three have since developed permanent AF. Three had pacemakers implanted between 40 and 47 years of age due to sick sinus syndrome and one suffered sudden cardiac death at the age of 64 ( Table 1) . None of the homozygous carriers had apparent structural heart disease at the time of AF diagnosis including no evidence of left ventricular hypertrophy (LVH) or conduction abnormalities on ECGs ( Table 1) . Echocardiograms were available for seven homozygotes and all had normal LV size and normal ejection fraction (EF) ( Table 2 ) at diagnosis. The latest available follow up studies 31-47 years after the initial diagnosis showed that two patients, both diagnosed in the interim with hypertension, had developed mild concentric LVH on echocardiograms (wall thickness 1.3-1.4 cm) with comparable voltage changes on ECG ( Table 2) . Both also developed mild-LV dilatation and one mildly depressed EF. One additional homozygote developed mild LV dilatation and another mildly depressed EF. Three homozygotes suffered ischemic stroke 35-56 years of age ( Table 1) . One was female but none had other known risk factors for stroke prior to the event. 18 One of these individuals later developed hypertension.
Discussion
We have found a frameshift deletion in the sarcomere gene MYL4 that causes early-onset AF. All eight homozygous carriers in our study were diagnosed with early-onset AF and six were diagnosed before they were 30 years old, a very early age for this arrhythmia. The frameshift mutation is in strong LD with several other noncoding sequence variants. It is possible that the observed association is caused by one of these other variants, but predicted loss of function variants are much more likely to associate with disease and to be the causal mutation than non-coding variants.
Myosin is a major component of the sarcomere, the building block the of the striated muscle contractile system. 19 Myosin is an ATPase cellular motor protein composed of two heavy chains and two pairs of light chains: the essential (ELC) and regulatory light chains. MYL4 encodes a 197 amino acid myosin ELC, also known as atrial light chain 1, expressed in cardiac and skeletal muscle of the fetus 20 and in the atria after birth. 21 Ventricular expression of MYL4 is reactivated in congenital heart diseases and cardiomyopathies and has been associated with improved contractile function. 22 To date, the only in vivo studies on the function of MYL4 were performed in zebrafish. 23, 24 carrying a C-terminal truncating mutation in cmlc1 shows severely reduced cardiac contractility but sarcomere structures appear normal, leading the authors to suggest a regulatory as well as a structural function for MYL4 24, 24 Sequence variants in MYL4 have not been associated with arrhythmias or other diseases previously. Arrhythmias are, however, commonly seen in cardiomyopathies caused by mutations in ventricular sarcomere genes and structural myocardial disease is a well-established major risk factor for conduction disturbance. For example, AF is found in over 20% of patients with hypertrophic cardiomyopathy, 25 a disease caused by mutations in genes encoding proteins of and associated with the sarcomere, including MYL3, the ventricular equivalent of MYL4. 21 In those cases, AF may be a consequence of structural and hemodynamic changes in the atria due to left ventricular disease.
There was no convincing evidence of overt structural heart disease associated with the MYL4 deletion in our study. However, mild or subclinical myopathy of the atria cannot be excluded based on the available data. During follow up, four patients developed mild ventricular cardiomyopathies, possibly the consequence of longstanding AF or other risk factors including hypertension. We have previously described the absence of apparent cardiomyopathy from carriers of a missense mutation in another atrial sarcomere gene, MYH6, that is associated with sick sinus syndrome and AF. 7 Another similarity of the MYL4 deletion with the MYH6 sarcomere mutation is the association with sick sinus syndrome and pacemaker implantation. Three of the eight homozygous carriers had required pacemaker implantation due to sick sinus syndrome, that while commonly seen with AF, is an uncommon syndrome in the young and middle aged population. 26 For comparison, of the 1944 individuals in our dataset who were diagnosed with early-onset AF (irrespective of genotype information), 128 (6.6%) have had a pacemaker implantation at any age. Interestingly, three of the eight individuals suffered ischemic stroke before the age of 60 years. Two would have been classified as low risk by the CHA2DS2-VASc criteria and one as low-moderate risk, the risk factor in that case being female gender. However gender is not considered a strong risk factor for stroke under the age of 65 years. 27 This suggests an unusually high risk of stroke in these patients, potentially related to underlying atrial cardiomyopathy, and raises the possibility of genotype-based risk stratification of atrial thrombus formation.
In conclusion, mutations in atrial sarcomere genes causing atrial arrhythmias suggest an important contribution of the cardiac contractile system to cardiac conduction and AF even in the absence of apparent cardiomyopathy. These findings may provide novel mechanistic insight into the pathophysiology of this complex arrhythmia.
